Protocol
Survodutide (10mg Vial)
Complete dosage protocol and reconstitution guide for Survodutide (10mg Vial).
Calculator preset
Run the vial math before tracking.
At ~5.0 mg/mL, 1 unit = 0.01 mL = 50 mcg on a U-100 syringe; 600 mcg = 12 units and 4800 mcg = 96 units .
01 · At a glance
Quickstart Highlights
Survodutide (BI 456906) is a dual glucagon/GLP‑1 receptor agonist investigated for obesity and related metabolic conditions. Clinical trials used once‑weekly subcutaneous injections with dose‑dependent weight loss during a 20‑week escalation and maintenance thereafter [1] . Gastrointestinal effects (nausea/diarrhea) were the most common adverse events and can be mitigated with slower escalation strategies [3] , with overall safety acceptable in studied populations [1] [12] .
02 · Dosing & reconstitution
Dosing & Reconstitution Guide
A practical calculator-ready setup based on the imported protocol reference. Use these values as a math starting point, then verify every entry against your own vial, diluent, and professional guidance.
Standard / Gradual Approach (2.0 mL = ~5.00 mg/mL)
600–4800 mcg once weekly with gradual titration anchored to clinical trial ranges [1] [3] . Insulin‑syringe math: At ~5.00 mg/mL, 1 unit = 0.01 mL ≈ 50 mcg on a U‑100 insulin syringe.
Reconstitution Steps
- Draw 2.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F) , protected from light.
03 · What you'll need
Supplies Needed
Keep this as a planning checklist. TNHL does not sell or verify supplies on this page, and no supplier quality claims are made here.
- 12 weeks (adds 1.8 mg phase): total ≈ 14.4 mg → 2 vials
- 16 weeks (adds 2.4 mg phase): total ≈ 24.0 mg → 3 vials
- 8 weeks: 8 syringes
- 12 weeks: 12 syringes
- 16 weeks: 16 syringes
- 8 weeks (1 vial): 2.0 mL → 1 × 10 mL bottle
- 12 weeks (2 vials): 4.0 mL → 1 × 10 mL bottle
- 16 weeks (3 vials): 6.0 mL → 1 × 10 mL bottle
- Per week: 2 swabs
- 8 weeks: 16 swabs → recommend 1 × 100‑count box
- 12 weeks: 24 swabs → recommend 1 × 100‑count box
- 16 weeks: 32 swabs → recommend 1 × 100‑count box
Protocol Overview
- Goal: Support clinically meaningful weight reduction and metabolic improvements over time [1] [3] .
- Schedule: Weekly subcutaneous injections for 8–12 weeks (optional extension to 16–24 weeks depending on tolerance and goals) [1] .
- Dose Range: 600–4800 mcg weekly (0.6–4.8 mg), escalating as tolerated within trial‑tested ranges [1] [3] .
- Reconstitution: 2.0 mL per 10 mg vial (~5.00 mg/mL) to keep higher weekly doses ≤1.0 mL.
- Storage: Lyophilized frozen; reconstituted refrigerated; avoid freeze–thaw cycles.
Dosing Protocol
- Suggested once‑weekly titration approach informed by clinical studies.
- Start: 600 mcg once weekly.
- Titrate: Increase by ~600 mcg every 4 weeks as tolerated (e.g., 0.6 → 1.2 → 1.8 → 2.4 mg; optional 3.6 → 4.8 mg) in line with dose ranges and escalation concepts used in trials [1] [3] .
- Frequency: Once per week (subcutaneous).
- Timing: Use a consistent weekly day/time; rotate injection sites.
- Note: Slower escalations can mitigate GI adverse events such as nausea and diarrhea [3] .
Storage Instructions
- Proper storage preserves peptide stability.
- Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); protect from light; avoid repeated freeze–thaw.
- Allow vials to reach room temperature before opening to reduce condensation.
04 · Good to know
Important Notes
- This Survodutide page is for educational research organization only.
- Confirm route, dose, contraindications, monitoring, storage, and cycle decisions with qualified professional guidance.
- Use sterile technique, rotate sites when applicable, and log missed doses, reactions, and inventory changes.
05 · How it works
How This Works
Survodutide (BI 456906) is a dual glucagon/GLP‑1 receptor agonist investigated for obesity and related metabolic conditions.
Clinical trials used once‑weekly subcutaneous injections with dose‑dependent weight loss during a 20‑week escalation and maintenance thereafter [1] .
Gastrointestinal effects (nausea/diarrhea) were the most common adverse events and can be mitigated with slower escalation strategies [3] , with overall safety acceptable in studied populations [1] [12] .
The library page pairs that educational context with calculator-ready vial math, so users can understand the protocol structure and then track their own entered values in one place.
06 · Daily habits
Lifestyle Factors
- Keep meals, training, sleep, and recovery notes in the journal so trends are easier to review.
- Track body metrics only if they are relevant to the user's goal and approved data sources.
- Use consistent timing and logging habits so adherence data is meaningful.
07 · What to expect
Potential Benefits & Side Effects
- Survodutide observations should be recorded conservatively: expected research endpoints, tolerability notes, injection-site reactions when applicable, sleep, appetite, energy, mood, and any adverse or unusual response.
- This section is not a claim of therapeutic benefit.
08 · Technique
Injection Technique
- Wash hands with soap and water.
- Wipe the vial stopper and chosen site with alcohol, then let both dry.
- Confirm the vial concentration, calculator result, and intended draw amount before loading the syringe.
- Use the route and needle technique directed by a qualified professional or product instructions.
- For subcutaneous injections, rotate sites and inject slowly to limit leakage and irritation.
- Do not reuse needles or syringes.
- Dispose of sharps in a puncture-resistant container.
- Return stored items promptly to the correct temperature.
- Log dose, site, date, time, inventory change, and any observation.
09 · Evidence